NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 26 to 50 of 1250

Display Results as:

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional) - PA-18-066

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. 

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional) - PA-18-067

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R34 

Summary: This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving andthe drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study.Of particular interest are prevention interventions targeting the healthcare system.  

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional) - PA-18-068

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R34 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies, designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches.  

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional) - PA-18-069

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R03 

Summary: This Funding Opportunity Announcement (FOA) encourages small grant applications (R03) to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.  

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional) - PA-18-070

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages R21 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.  

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional) - PA-18-071

Organization: NIDA 

Posting Date: 11-15-2017 

Expiration Date: 05-08-2018 

Activity Code: R34 

Summary: This FOA provides resources to support (a) pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; (b) pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or (c) pilot or feasibility studies to increase the scale, uptake, delivery, and/or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection or may affect transmission risk behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection and/or drug use are emergent.  

Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (R01 Clinical Trial Optional) - PA-18-191

Organization: NIAAA 

Posting Date: 11-01-2017 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function with a goal toward improving the outcome of patients who abuse alcohol.  

Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R01 Clinical Trial Required) - PA-18-192

Organization: NIAAA 

Posting Date: 11-06-2017 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: The objective of this Funding Opportunity Announcement (FOA) is to encourage applications that use human laboratory paradigms and/or clinical trials to evaluate the safety and efficacy of novel or re-purposed compounds, that bind to new targets, for treatment of alcohol use disorder (AUD) or AUD with a comorbid post-traumatic stress disorder. 

Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R03 Clinical Trial Optional) - PA-18-200

Organization: NIAAA 

Posting Date: 11-06-2017 

Expiration Date: 05-08-2018 

Activity Code: R03 

Summary: The objective of this Funding Opportunity Announcement (FOA) is to encourage research on screening and brief interventions to prevent and/or reduce alcohol use and alcohol-related harms among underage and young adult populations. 

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional) - PA-18-134

Organization: NINR 

Posting Date: 11-03-2017 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. 

Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional) - PA-18-135

Organization: NINR 

Posting Date: 11-01-2017 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn. 

Functional Wellness in HIV: Maximizing the Treatment Cascade (R01 Clinical Trial Optional) - PA-18-136

Organization: NINR 

Posting Date: 11-03-2017 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.  

Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional) - PA-18-153

Organization: NINR 

Posting Date: 11-03-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. 

Functional Wellness in HIV: Maximizing the Treatment Cascade (R21 Clinical Trial Optional) - PA-18-154

Organization: NINR 

Posting Date: 11-03-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: The National Institute of Nursing Research (NINR) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. 

Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R21 Clinical Trial Required) - PA-18-197

Organization: NIAAA 

Posting Date: 11-06-2017 

Expiration Date: 05-08-2018 

Activity Code: R21 

Summary: The objective of this Funding Opportunity Announcement (FOA) is to encourage applications that use human laboratory paradigms and/or clinical trials to evaluate the safety and efficacy of novel or re-purposed compounds, that bind to new targets, for treatment of alcohol use disorder (AUD) or AUD with a comorbid post-traumatic stress disorder. 

Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R03 Clinical Trial Required) - PA-18-198

Organization: NIAAA 

Posting Date: 11-06-2017 

Expiration Date: 05-08-2018 

Activity Code: R03 

Summary: The objective of this Funding Opportunity Announcement (FOA) is to encourage applications that use human laboratory paradigms and/or clinical trials to evaluate the safety and efficacy of novel or re-purposed compounds, that bind to new targets, for treatment of alcohol use disorder (AUD) or AUD with a comorbid post-traumatic stress disorder. 

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional) - PAR-18-221

Organization: NIDA 

Posting Date: 11-29-2017 

Expiration Date: 05-08-2018 

Activity Code: UH2/UH3 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. 

NHLBI Career Transition Award for Intramural Fellows (K22) (Clinical Trials Required) - PAR-18-424

Organization: NHLBI 

Posting Date: 11-28-2017 

Expiration Date: 05-08-2018 

Activity Code: K22 

Summary: The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #). 

NHLBI Career Transition Award for Intramural Fellows (K22) (No Independent Clinical Trials) - PAR-18-416

Organization: NHLBI 

Posting Date: 11-28-2017 

Expiration Date: 05-08-2018 

Activity Code: K22 

Summary: The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (TEMP-229). 

Personalized Strategies to Manage Symptoms of Chronic Illness (R15 Clinical Trial Not Allowed) - PA-18-472

Organization: NINR 

Posting Date: 12-18-2017 

Expiration Date: 05-08-2018 

Activity Code: R15 

Summary: The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. 

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional) - PA-18-568

Organization: NIDA 

Posting Date: 01-09-2018 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDA's international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. 

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional) - PA-18-569

Organization: NIDA 

Posting Date: 01-17-2018 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services. 

Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp) - PA-18-713

Organization: NIH 

Posting Date: 03-15-2018 

Expiration Date: 05-08-2018 

Activity Code: (Admin Supp) 

Summary: The National Institutes of Health (NIH) Office of the Director announces the availability of administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) are notified that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. SGM populations include, but are not limited to, lesbian, gay, bisexual, and transgender people, and individuals with differences or disorders of sexual development (sometimes referred to as intersex or as specific diagnoses). This trans-NIH effort, which involves multiple Institutes, Centers and Offices from across NIH, is intended to encourage investigation in this growing, field of research. To increase our collective understanding of the broad range of research needed to address the unique health issues of SGM populations, the supplement will focus on areas of research interest, including, but not limited to: studies on increased disease risk; mental, behavioral and social health; approaches to personalized medicine; access to care; reprod 

Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) - PAR-16-117

Organization: NIAID 

Posting Date: 03-03-2016 

Expiration Date: 05-09-2018 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research that addresses one or both of the following objectives: Devise optimal strategies to improve the identification of persons unaware of their HIV-1 infection and successfully link them to HIV testing, treatment, and prevention interventions. Develop and examine the feasibility and acceptability of novel integrated interventions of biomedical and behavioral strategies that substantially reduce the likelihood of onward HIV transmission in these populations. 

Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01 Clinical Trial Optional) - PAR-18-254

Organization: NIAID 

Posting Date: 11-29-2017 

Expiration Date: 05-09-2018 

Activity Code: R01 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research that addresses one or both of the following objectives: Devise optimal strategies to improve the identification of persons unaware of their HIV-1 infection and successfully link them to HIV testing, treatment, and prevention interventions. Develop and examine the feasibility and acceptability of novel integrated interventions of biomedical and behavioral strategies that substantially reduce the likelihood of onward HIV transmission in these populations. 

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

RMOD

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top